Nimodipine extended-release tablets

Nimodipine is a Ca2 channel blocker. Under normal circumstances, the contraction of smooth muscle depends on the entry of Ca2 into the cell, causing the depolarization of the transmembrane current. Nimodipine achieves the purpose of relieving vasospasm by effectively preventing Ca2 from entering the cell and inhibiting the contraction of smooth muscle. Animal experiments have shown that the effect of nimodipine on cerebral arteries is much stronger than that on arteries in other parts of the body, and because it has a high lipophilic characteristic, it is easy to pass through the blood-brain barrier. When used for the treatment of subarachnoid hemorrhage, the concentration in cerebrospinal fluid can reach 12.5ng/ml. It can be inferred that it can be used clinically to prevent vasospasm after subarachnoid hemorrhage, but the mechanism of action of this drug in human application is still unclear. In addition, it also has the effect of protecting and promoting memory and promoting intellectual recovery. Therefore, it can selectively act on cerebral vascular smooth muscle, dilate cerebral blood vessels, increase cerebral blood flow, and significantly reduce ischemic brain damage caused by vasospasm.

Nimodipine.

This product is light yellow tablet.

Used for ischemic cerebrovascular disease, migraine, cerebral vasospasm caused by mild subarachnoid hemorrhage, sudden deafness and mild to moderate hypertension.

Oral administration: 30-60 mg at a time, twice a day.

The following adverse reactions may occur with the regular-release preparation of nimodipine: feeling of heat, flushing of the skin, drop in blood pressure (especially in patients with pre-existing high blood pressure), increased heart rate, dizziness, headache, gastrointestinal discomfort, weakness, and peripheral edema. A small number of patients may experience symptoms of overreaction of the central nervous system, such as insomnia, restlessness, agitation, irritability, and sweating. Some patients may experience excessive exercise, depression, and thrombocytopenia.

Patients with severe liver damage are contraindicated. It is not recommended to take nimodipine and anti-epileptic drugs at the same time.

Precautions for children: This experiment has not been conducted and there is no reliable reference. Precautions for pregnancy and lactation: The drug can be secreted by breast milk, so it should not be used by lactating women. Precautions for the elderly: This experiment has not been conducted and there is no reliable reference.

1. When used in combination with other calcium ion antagonists that act on the cardiovascular system, it can increase the effectiveness of other calcium ion antagonists. 2. When nimodipine 90 mg/day is used in combination with cimetidine 1000 mg/day for more than one week, the blood concentration of nimodipine can increase by 50%, which may be related to the inhibition of nimodipine metabolism by cimetidine in the liver cytochrome P450.

Keep away from light, tightly closed and in a dry place.

60mg

24 months

Qilu Pharmaceutical Co., Ltd.

• Founded in:

  1992-08-21

• Address:

  No. 317, Xinluo Street, High-tech Zone, Jinan City, Shandong Province

• Tax NO.:

  91370000614073351Q

• Registered Funds:

  600 million yuan

• Website:

  Log in to view

• Email:

  Log in to view